CALT News and Press, Calliditas Therapeutics AB From 08/19/21

Calliditas Therapeutics: Interim Report Q2, 2021 Filing of Marketing Authorisation Application on accelerated basis with EMA PR Newswire STOCKHOLM , Aug. 19, 2021 /PRNewswire/ -- "Following the filing for accelerated approval with the FDA in Q1, we filed our ...

Qualigen Therapeutics QLGN -29% on Q2 earnings release Sema4 Holdings SMFR -20% on Q2 earnings release Lightning eMotors ZEV -14% on Q2 earnings release Arcimoto FUV -13% on Q2 earnings release Calliditas Therapeutics (NASDAQ:CALT) -13%. Romeo Power RMO...

Gainers: NanoVibronix (NASDAQ:NAOV) +47%. Enlivex Therapeutics (NASDAQ:ENLV) +20%. GoHealth (NASDAQ:GOCO) +16%. Travere Therapeutics (NASDAQ:TVTX) +16%. Collegium Pharmaceutical (NASDAQ:COLL) +16%. Auddia (NASDAQ:AUUD) +15%. AudioEye (NASDAQ:AEYE) +14%. Cohen & Company (NYSE:COHN) +14%. F...

Calliditas Therapeutics has resolved on a directed share issue in the amount of 2.4 million shares, raising proceeds of approximately SEK 324 million PR Newswire NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STA...

The FDA has granted Fast Track Designation to Calliditas Therapeutics' (NASDAQ:CALT) lead NOX inhibitor candidate setanaxib for the treatment of patients with the chronic orphan liver disease primary biliary cholangitis (PBC). Fast Track status provides for more frequent interaction with the ...

Calliditas Receives FDA Fast Track Designation for setanaxib in PBC PR Newswire STOCKHOLM , Aug. 9, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the U.S. Food and Drug Administr...

Calliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in Europe Calliditas and STADA partner to bring a specialty therapy focused on downregulating IgA1 to European patients. If approved, it would be the first-ever approved...

Calliditas secures $75 million term loan facility PR Newswire STOCKHOLM , July 15, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has signed a loan agreement of up to the ...

Calliditas Therapeutics (CALT) announces that the company submitted a Marketing Authorisation Application ((MAA)) to the European Medicines Agency ((EMA)) for nefecon, a novel oral formulation targeting down regulation of IgA1 for the treatment of primary IgA Nephropathy ((IgAN)), a form of k...

Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency PR Newswire STOCKHOLM , May 28, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today...